ritanserin has been researched along with Substance Withdrawal Syndrome in 12 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the ability of ritanserin, a 5-HT2 antagonist, to modify ethanol withdrawal (EW) symptoms in two animal models of anxiety: the elevated plus-maze (EPM) and the pentylenetetrazol (PTZ) discrimination assay." | 7.70 | Effects of ritanserin on ethanol withdrawal-induced anxiety in rats. ( Gatch, MB; Lal, H; Wallis, CJ, 2000) |
| "Ritanserin is a potent long-acting 5-HT2 antagonist that acts centrally." | 6.39 | Ritanserin and alcohol abuse and dependence. ( Meert, TF, 1994) |
| " Single doses of 5-HT2 antagonists, mianserin (5mg/kg) and ritanserin (1mg/kg), effectively ameliorated withdrawal anxiety in the rat, returning behavioural function in the social interaction test and elevated plus maze to levels comparable to vehicle-treated animals." | 3.73 | Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists. ( Begg, DP; Hallam, KT; Norman, TR, 2005) |
| "This study investigated the ability of ritanserin, a 5-HT2 antagonist, to modify ethanol withdrawal (EW) symptoms in two animal models of anxiety: the elevated plus-maze (EPM) and the pentylenetetrazol (PTZ) discrimination assay." | 3.70 | Effects of ritanserin on ethanol withdrawal-induced anxiety in rats. ( Gatch, MB; Lal, H; Wallis, CJ, 2000) |
| " Ritanserin discontinuation following chronic dosing in healthy volunteers does not appear to be associated with withdrawal symptoms." | 2.67 | Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers. ( Ashton, CH; Emanuel, MB; Hammond, GL; Kamali, F; Rawlins, MD; Stansfield, SC, 1992) |
| "Ritanserin is a potent long-acting 5-HT2 antagonist that acts centrally." | 2.39 | Ritanserin and alcohol abuse and dependence. ( Meert, TF, 1994) |
| "01 mg/kg IP, twice daily for 14 days) produced a significant anxiolytic profile which was not a result of handling during the chronic dosing schedule, an effect was not measureable 24 h after treatment ended." | 1.28 | Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. ( Heaton, M; Marsden, CA; Upton, N; Wright, IK, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schrott, LM | 1 |
| Baumgart, MI | 1 |
| Zhang, X | 1 |
| Sparber, SB | 2 |
| Overstreet, DH | 1 |
| Knapp, DJ | 1 |
| Moy, SS | 1 |
| Breese, GR | 1 |
| Begg, DP | 1 |
| Hallam, KT | 1 |
| Norman, TR | 1 |
| Harvey, BH | 1 |
| Retief, R | 1 |
| Korff, A | 1 |
| Wegener, G | 1 |
| Meert, TF | 2 |
| Gatch, MB | 1 |
| Wallis, CJ | 1 |
| Lal, H | 1 |
| Myrick, H | 1 |
| Brady, KT | 1 |
| Malcolm, R | 1 |
| Wright, IK | 1 |
| Heaton, M | 1 |
| Upton, N | 1 |
| Marsden, CA | 1 |
| Kamali, F | 1 |
| Stansfield, SC | 1 |
| Ashton, CH | 1 |
| Hammond, GL | 1 |
| Emanuel, MB | 1 |
| Rawlins, MD | 1 |
| Dugovic, C | 1 |
| Ashton, D | 1 |
| Clincke, GH | 1 |
| Neal, BS | 1 |
| Adam, K | 1 |
| Oswald, I | 1 |
2 reviews available for ritanserin and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Ritanserin and alcohol abuse and dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Discrimination Learning; Disease Mo | 1994 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carb | 2001 |
1 trial available for ritanserin and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers.
Topics: Adolescent; Adult; Anxiety; Depression; Double-Blind Method; Female; Humans; Male; Ritanserin; Singl | 1992 |
9 other studies available for ritanserin and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Prenatal opiate withdrawal activates the chick embryo hypothalamic pituitary-adrenal axis and dilates vitelline blood vessels via serotonin(2) receptors.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Chick Embryo; Corticosterone; Disease Models, Animal; Hypothal | 2002 |
A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.
Topics: Aminopyridines; Animals; Anxiety; Buspirone; Dose-Response Relationship, Drug; Ethanol; Ethylamines; | 2003 |
Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Diazepam; Disease Models, Animal; Interpers | 2005 |
Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: role of 5HT 2A/C-receptors.
Topics: Animals; Antidepressive Agents, Tricyclic; Hippocampus; Imipramine; Male; Nitric Oxide Synthase Type | 2006 |
Effects of ritanserin on ethanol withdrawal-induced anxiety in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Central Nervous System Depressants; Discrimination Learning; | 2000 |
Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.
Topics: Adrenergic alpha-Antagonists; Animals; Anti-Anxiety Agents; Diazepam; Dioxanes; Idazoxan; Imidazoles | 1992 |
Effects of ritanserin and chlordiazepoxide on sleep-wakefulness alterations in rats following chronic cocaine treatment.
Topics: Animals; Chlordiazepoxide; Cocaine; Male; Rats; Rats, Inbred Strains; Ritanserin; Sleep; Sleep, REM; | 1992 |
The serotonin2 antagonist ritanserin blocks quasi-morphine withdrawal at a time when mianserin is no longer effective.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Conditioning, Operant; Male; Mianserin; Morphine Dependence; N | 1990 |
Effects of repeated ritanserin on middle-aged poor sleepers.
Topics: Attention; Electroencephalography; Female; Humans; Male; Middle Aged; Piperidines; Ritanserin; Serot | 1989 |